180 Wealth Advisors LLC Invests $255,000 in DexCom, Inc. (NASDAQ:DXCM)

180 Wealth Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 3,280 shares of the medical device company's stock, valued at approximately $255,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Cullen Investment Group LTD. grew its position in shares of DexCom by 5.6% during the 4th quarter. Cullen Investment Group LTD. now owns 11,502 shares of the medical device company's stock worth $895,000 after buying an additional 614 shares during the period. CHICAGO TRUST Co NA boosted its stake in DexCom by 67.9% in the fourth quarter. CHICAGO TRUST Co NA now owns 18,236 shares of the medical device company's stock valued at $1,418,000 after acquiring an additional 7,373 shares during the last quarter. Capital Investment Advisors LLC acquired a new stake in DexCom during the 4th quarter worth $206,000. Czech National Bank grew its holdings in DexCom by 3.7% during the 4th quarter. Czech National Bank now owns 84,689 shares of the medical device company's stock worth $6,586,000 after acquiring an additional 3,057 shares during the period. Finally, Watts Gwilliam & Co. LLC bought a new stake in shares of DexCom during the 4th quarter valued at $3,334,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent research reports. Oppenheimer reduced their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein raised their target price on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Leerink Partners lowered their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. StockNews.com lowered shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Finally, JPMorgan Chase & Co. upped their target price on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $99.29.

DexCom Stock Up 5.5 %

Shares of DXCM traded up $4.44 during midday trading on Thursday, hitting $84.84. The stock had a trading volume of 5,998,762 shares, compared to its average volume of 3,834,166. The firm has a market cap of $33.14 billion, a price-to-earnings ratio of 50.80, a price-to-earnings-growth ratio of 2.00 and a beta of 1.12. The company has a 50 day simple moving average of $77.89 and a two-hundred day simple moving average of $78.41. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the firm's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.